Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Portfolio
Trending News
More News >
News
Enterprise Solutions
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
RNAC
Stock Latest News
The Fly
Seven new option listings and one option delisting on April 16th
5d ago
AVTX
CARA
Premium
Ratings
Buy Rating Affirmed for Cartesian Therapeutics Due to Promising Phase 2b Trial Results and Strong Safety Profile
12d ago
RNAC
Premium
Ratings
Promising Growth Potential for Cartesian Therapeutics: Buy Rating Affirmed by Analyst Gil Blum
13d ago
RNAC
Premium
Ratings
Promising Potential of Cartesian Therapeutics’ Descartes-08 in gMG Treatment: A Buy Recommendation
13d ago
RNAC
Premium
Ratings
Promising Clinical Data and Future Prospects Drive Buy Rating for Cartesian Therapeutics
13d ago
RNAC
Premium
Company Announcements
Cartesian Therapeutics Unveils Promising Phase 2b Trial Results
14d ago
8K
RNAC
Premium
The Fly
Cartesian Therapeutics announces data from Phase 2b trial of Descartes-08
14d ago
RNAC
Premium
The Fly
Cartesian Therapeutics announces employment inducement grants
20d ago
RNAC
Premium
Ratings
Buy Rating for Cartesian Therapeutics: Promising Advancements in Biopharmaceuticals and Strategic Clinical Progress
1M ago
RNAC
Premium
The Fly
Cartesian price target lowered to $40 from $45 at H.C. Wainwright
1M ago
RNAC
Premium
Company Announcements
Cartesian Therapeutics Faces Financial Risk from Goodwill and Intangible Asset Impairments Post-Merger
1M ago
RNAC
Premium
Company Announcements
Cartesian Therapeutics Advances mRNA Therapy Pipeline
1M ago
RNAC
Premium
Ratings
Buy Rating for Cartesian Therapeutics: Promising Clinical Developments and Strong Financial Position
1M ago
RNAC
Premium
The Fly
Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer
1M ago
AMGN
RNAC
Premium
The Fly
Cartesian Therapeutics reports FY24 EPS ($4.49) vs. ($49.76) last year
1M ago
RNAC
Premium
The Fly
Cartesian Therapeutics sees cash runway into mid-2027
1M ago
RNAC
Premium
The Fly
Cartesian Therapeutics announces employment inducement grant
2M ago
RNAC
Premium
Pre-Earnings
Is RNAC a Buy, Before Earnings?
2M ago
RNAC
Premium
Company Announcements
Cartesian Therapeutics Advances Descartes-08 in Clinical Trials
2M ago
8K
RNAC
Premium
Ratings
Innovative mRNA-Based CAR-T Therapy Positions Cartesian Therapeutics for Market Leadership
2M ago
RNAC
Premium
The Fly
Cartesian Therapeutics announces new employment inducement grants
2M ago
RNAC
Premium
The Fly
Cartesian Therapeutics announces FDA SPA agreement for Phase 3 AURORA trial
3M ago
RNAC
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
